ACBD6

Across TCGA pan-cancer cohorts, ACBD6 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ACBD6 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ACBD6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACBD6 expression acts as an unfavorable survival marker.

SCLC, COAD, and ACC are the cancer types where ACBD6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.192	0.699	.002	18	view →
COAD	OS	Median	All	0.111	0.871	<.001	12	view →
ACC	DFS	Median	All	0.209	0.659	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ACBD6–SCLC (OS)

Open the SCLC breakdown →